Aldeyra Therapeutics (ALDX) Stock Price, News & Analysis

Company Overview

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.

Key Stats

• Today's Range: $2.65 to $2.82
• 50-Day Range: $1.42 to $6.98
• 52-Week Range: $1.14 to $7.20
• Volume: 577,397 shs
• Average Volume: 727,140 shs
• Market Capitalization: $169.21 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.67
• Consensus Rating: Buy

Aldeyra Therapeutics Stock Analysis - MarketRank™

Aldeyra Therapeutics scored higher than 47% of companies evaluated by MarketBeat, and ranked 351st out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Aldeyra Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Aldeyra Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Aldeyra Therapeutics are expected to grow in the coming year, from ($0.92) to ($0.17) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Aldeyra Therapeutics is -2.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Aldeyra Therapeutics is -2.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Aldeyra Therapeutics has a P/B Ratio of 1.37. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.91% of the float of Aldeyra Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Aldeyra Therapeutics has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Aldeyra Therapeutics has recently increased by 21.41%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Aldeyra Therapeutics does not currently pay a dividend.

Dividend Growth

Aldeyra Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

7.91% of the float of Aldeyra Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Aldeyra Therapeutics has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Aldeyra Therapeutics has recently increased by 21.41%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.20

News Sentiment

Aldeyra Therapeutics has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.83 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 19 news articles for Aldeyra Therapeutics this week, compared to 3 articles on an average week.

Search Interest

17 people have searched for ALDX on MarketBeat in the last 30 days. This is an increase of 70% compared to the previous 30 days.

MarketBeat Follows

4 people have added Aldeyra Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Aldeyra Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,828,000.00 in company stock.

Percentage Held by Insiders

Only 8.50% of the stock of Aldeyra Therapeutics is held by insiders.

Percentage Held by Institutions

59.71% of the stock of Aldeyra Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ALDX Stock Analysis - Frequently Asked Questions

How have ALDX shares performed this year?

Aldeyra Therapeutics' stock was trading at $4.99 at the start of the year. Since then, ALDX stock has decreased by 44.2% and is now trading at $2.7850.
View the best growth stocks for 2025 here.

How were Aldeyra Therapeutics' earnings last quarter?

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) released its quarterly earnings results on Thursday, March, 6th. The biotechnology company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of $0.03 by $0.30.

Who are Aldeyra Therapeutics' major shareholders?

Top institutional shareholders of Aldeyra Therapeutics include Woodstock Corp (0.37%), Bank of New York Mellon Corp (0.19%), Hennion & Walsh Asset Management Inc. (0.12%) and PFG Investments LLC (0.09%). Insiders that own company stock include Perceptive Advisors Llc, Todd C Brady, Bruce Greenberg, Martin Joseph Joyce and Nancy Miller-Rich.
View institutional ownership trends.

How do I buy shares of Aldeyra Therapeutics?

Shares of ALDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Aldeyra Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Aldeyra Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), Viking Therapeutics (VKTX), Alibaba Group (BABA) and Netflix (NFLX).

Company Calendar

• Last Earnings: 3/06/2025
• Today: 5/02/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:ALDX
• CIK: 1341235
• Web: www.ampliphibio.com
• Phone: 781-761-4904
• Fax: 781-270-0630
• Employees: 15
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $9.67
• High Stock Price Target: $10.00
• Low Stock Price Target: $9.00
• Potential Upside/Downside: +256.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.94)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-37,540,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -43.01%
• Return on Assets: -33.62%

Debt

• Debt-to-Equity Ratio: 0.18
• Current Ratio: 6.80
• Quick Ratio: 6.80

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.04 per share
• Price / Book: 1.33

Miscellaneous

• Outstanding Shares: 59,896,000
• Free Float: 54,488,000
• Market Cap: $162.32 million
• Optionable: Optionable
• Beta: 0.94